Generic Name: nelarabine

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Chemotherapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Arranon is a nucleoside inhibitor approved for refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

General Info

Arranon is a defective DNA building block that halts cell replication. Studies showed it reduces the number of cancerous cells in people with certain types of T cell leukemia and lymphoma.


Dosing Info:

Arranon is given as an intravenous infusion. It may be used by both adults and children.

Side Effects

Common side effects include nausea, diarrhea, vomiting, constipation, fatigue, fever, cough and shortness of breath. Arranon can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. The Arranon label has a warning about severe neurological side effects including altered mental state, convulsions and peripheral nerve damage. Arranon may cause fetal harm if used during pregnancy.

For More Info:

Co-Pay Program Info:

Last Reviewed: November 29, 2018